StockData

Alps vs BioNexus Gene Lab

ALPS and BGLC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALPS and BGLC compare

Alps grew revenue faster over the last twelve months (44.1% versus −67.3% for BioNexus Gene Lab).

Alps keeps more of each dollar of sales as profit, with a net margin of −41.4% compared with −82.4% at BioNexus Gene Lab.

BioNexus Gene Lab scores higher on the StockData Score (8 against 4 for Alps), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALPSBGLC
Size and price
Market cap–$2.4M
Share price$1.18$0.821
Change, 1 year−71.2%−83.0%
Change, 5 years–−99.6%
Beta (5Y)0.220.87
Employees896
StockData Score
Total score48 (better)
Valuation score03 (better)
Growth score1 (better)0
Performance score00
Health score35 (better)
Dividend score00
Valuation
P/S–0.8×
P/B–0.3×
FCF yield–−35.4%
Fair value–$7.45
Margin of safety–89.0%
Growth
Revenue growth (TTM)44.1% (better)−67.3%
Revenue growth, 5Y average–−8.2%
Profitability
Gross margin32.1% (better)12.3%
Operating margin−41.8% (better)−81.8%
Net margin−41.4% (better)−82.4%
FCF margin−54.2%−27.3% (better)
Return on equity–−33.7%
Return on invested capital–−32.3%
Financial health
Debt / equity–0.00
Interest coverage−40.2×–
Current ratio0.366.08 (better)
Altman Z-score–0.32
Piotroski F-score44
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–0.49%
Held by insiders61.4%31.0%
Short interest, % of float–0.16%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.